Renal Cell Carcinoma Advisor Videos - Cancer Therapy Advisor

Renal Cell Carcinoma Advisor Videos

Chapter 1

Targeted Therapy in Locally Advanced RCC

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss treatment options and ongoing research related to locally advanced renal cell carcinoma (RCC).

Chapter 2

The Role of Neoadjuvant Therapy

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the role of neoadjuvant therapy in the treatment of patients with renal cell carcinoma (RCC).

Chapter 3

Surgical Options – Ablative Techniques

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the preferred surgical options for patients with kidney cancer.

Chapter 4

Surgical Options – Lymph Node

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the standards for decision making related to lymph node dissection in patients with renal cell carcinoma (RCC).

Chapter 5

Surgical Options – Cytoreductive Nephrectomy

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the paradigm of cytoreductive nephrectomy and its role in the management of metastatic renal cell carcinoma (RCC).

Chapter 6

Tyrosine Kinase Inhibitors - First-Line Therapy

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the use of tyrosine kinase inhibitors in patients with advanced renal cell carcinoma and how they differ from other targeted therapies.

Chapter 8

Biomarkers in Renal Cell Carcinoma

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss biomarkers and how they relate to the treatment of advanced renal cell carcinoma (RCC).

Chapter 9

The MET Pathway

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss a newer potential target in RCC—MET.

Chapter 10

Checkpoint Inhibitors

Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, review the role of checkpoint inhibitors in the treatment of patients with kidney cancer.

Next hm-playlist in Renal Cell Carcinoma